Braf mutations are associated with high levels of phosphorylated RKIP in melanoma cell lines: Potential prognostic significance

Forum on Immunopathological Diseases and Therapeutics

Volumn 2, Issue 2, 2011, Pages 189-194

  Huerta Yepez, Sara ^a   Ekmekcioglu, S ^b   Rivera Pazos, C M ^a   Antonio Andres, G ^a   Vega, M I ^c   Baay Guzman, G ^a   Grimm, E ^b  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Unidad de Investigacion en Inmunologia e Infectologia   (Mexico)

Author keywords

BRAF mutation; Melanoma; NRAS mutation; Phospho RKIP; Prognosis

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C;

CONFERENCE PAPER; EARLY DIAGNOSIS; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOSURVEILLANCE; MELANOGENESIS; MELANOMA CELL; METASTASIS POTENTIAL; NONHUMAN; ONCOGENE; ONCOGENE BRAF; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY; TISSUE MICROARRAY;

EID: 79958268593     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.v2.i2.100     Document Type: Conference Paper

References (30)

1. Ugurel S, Utikal J, Becker JC. Tumor biomarkers in melanoma. Cancer Control. 2009;16(3):219-24.
2. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol Surg. 1996;22(3):217-26. (Pubitemid 26088386)
3. Boring CC, Squires TS, Tong T. Cancer statistics. Bol Asoc Med P R. 1991;83(6):225-42.
4. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23(21):4735-41. (Pubitemid 46224077)
5. Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2005;14(3):562-6. (Pubitemid 40489195)
6. Henriksen T, Dahlback A, Larsen SH, Moan J. Ultraviolet-radiation and skin cancer: effect of an ozone layer depletion. Photochem Photobiol. 1990;1(5):579-82.
7. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131-49. (Pubitemid 38812179)
8. Brown TJ, Nelson BR. Malignant melanoma: a clinical review. Cutis. 1999;63(5):275-4.
9. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet. 2009;126(4): 499-510.
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892): 949-54. (Pubitemid 34716871)
11. Meyer P, Sergi C, Garbe C. Polymorphisms of the BRAF gene predispose males to malignant melanoma. J Carcinog. 2003;2(1):7.
12. Schrama D, Keller G, Houben R, Ziegler CG, Vetter-Kauczok CS, Ugurel S. BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. J Carcinog. 2008;7:1.
13. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol. 2008;128(8):2003-12. (Pubitemid 352001214)
14. Eskandarpour M, Huang F, Reeves KA, Clark E, Hansson J. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer. 2009;124(1):16-26.
15. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008;1(4):395-405.
16. Zaidi MR, Day CP, Merlino G. From UVs to metastases: modeling melanoma initiation and progression in the mouse. J Invest Dermatol. 2008;128(10):2381- 91.
17. Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol. 2008;128(11):2575-95.
18. Rath O, Park S, Tang HH, Banfield MJ, Brady RL, Lee YC. The RKIP (Raf-1 kinase inhibitor protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cell Signal. 2008;20(5):935-41.
19. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signalregulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol. 2001;21(17):5958-69. (Pubitemid 32737812)
20. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate. 2006;66(3):248-56. (Pubitemid 43191224)
21. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 2009;7(6):832-40.
22. Zhang L, Fu Z, Binkley C, Giordano T, Burant CF, Logsdon CD. Raf kinase inhibitory protein inhibits beta-cell proliferation. Surgery. 2004;136(3):708-15. (Pubitemid 39186587)
23. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol. 2007;127(5):820-7.
24. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res. 2003;63(18):5669-73. (Pubitemid 37187459)
25. Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, Louis G. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem. 2003;278(11):9790-5. (Pubitemid 36800479)
26. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. RKIP sensitizes prostate and breast cancer cells to druginduced apoptosis. J Biol Chem. 2004;279(17):17515-23. (Pubitemid 38560515)
27. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169-200. (Pubitemid 39140959)
28. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature. 2003;426(6966):574-9. (Pubitemid 37522645)
29. Park S, Yeung ML, Beach S, Shields JM, Yeung KC. RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene. 2005;24(21):3535-40. (Pubitemid 40756254)
30. Huerta-Yepez S, Ekmekcioglu S, Rivera-Pazos CM, Antonio-Andres G, Vega MI, Baay-Guzman G, Melaponte G, Baritaki S, Yeung K, Grimm E, Bonavida B. BRAF and NRAS mutations in melanoma regulate the phosphorylation and inactivation of RKIP, the metastasis suppressor and immune surveillance cancer gene product. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. 2010;51:819.